Analytical Chemistry and Pharmacology Core Facility

分析化学和药理学核心机构 该核心的目标是通过分析化学和药理学基础设施和方法来支持小分子和纳米颗粒抗癌药物的转化开发。分子治疗项目的扩展、用于评估抗癌药物的临床前模型的开发以及新的北卡罗来纳州癌症医院临床试验部门的开放， 应用药理学服务的需求。Zamboni博士的招募和癌症中心机构资金的大量投资启动了核心及其运营。这个新的核心是由转化肿瘤学和纳米颗粒药物开发计划（TOND 2 I）实验室（于2009年3月开放）和GLP生物分析设施（将于2010年2月开放）。该核心所提供的技术和资源以前在IBM是没有的。此外，GLP生物分析设施是学术中心中为数不多的GLP实验室之一。核心资源将通过提供进行分析和药理学研究的杰出专业知识， 最高质量的数据和执行这些研究在成本效益的方式。 核心服务包括：GLP和非GLP水平的分析研究;药物制剂的开发;生物基质中分析测定的开发和验证;样品分析;药代动力学和药效学数据分析;以及纳米颗粒药理学的专门方法。这方面的一个例子是与Sharpless，Collichio和Ollila博士的合作，我们目前正在评估影响抗癌药物在异种移植和基因工程小鼠模型（GEMM）中的肿瘤递送的因素黑色素瘤和皮肤黑色素瘤患者。 未来的计划是扩大研究中心成员的研究，并利用该中心的资源招募新的抗癌药物。核心要求160，846美元，占其运营成本的15%;癌症中心成员占核心用户的96%。这个新的核心将是中心的巨大资产。

Analytical Chemistry and Pharmacology Core Facility The goal of this core is to support the translational development of small molecule and nanoparticle anticancer agents via analytical chemistry and pharmacologic infrastructure and methodologies. The expansion of the MolecularTherapeutics Program, development of preclinical models used to evaluate anticancer agents and the opening of new North Carolina Cancer Hospital's Clinical Trials Unit created the demand for applied pharmacology services. The recruitment of Dr. Zamboni and the substantial investment of cancer center institutional funds launched the core and its operations. This new core is comprised of the Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab (opened in March'09) and the UNC GLP Bioanalytical Facility (will open in Feb'10). The technologies and resources offered by this core were not previously available at UNC. Moreover, the UNC GLP Bioanalytical Facility is one of the few such GLP labs that exist in an academic center. The core resources will expand researchers' horizons and funding by providing outstanding expertise in performing analytical and pharmacology studies, providing the highest quality of data and performing these studies in a cost effective manner. The core's sen/ices consist of: analytical studies at GLP and non-GLP levels; development of drug formulations; development and validation of analytical assays In biological matrices; sample analysis; pharmacokinetic and pharmacodynamic data analysis; and specialized methods for nanoparticle pharmacology. An example of this is the collaboration with Drs. Sharpless, Collichio and Ollila, where we are currently evaluating the factors affecting the tumor delivery of anticancer agents in xenograft and genetically engineered mouse models (GEMM) of melanoma and in patients with cutaneous melanoma. Future plans are to expand the research of UNC LCCC members and use the resources of this core to recruit novel anticancer agents to UNC. The core requests $160,846, representing 15% of its operating costs; Cancer Center members constitute 96% of the core's users. This new core will be a tremendous asset to the center.